Publications 2024

Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T et al. (2024)
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science, 383 (6682), eadi5798
DOI 10.1126/science.adi5798, PubMed 38301010

Publications 2023

Andersen AN, Brodersen AM, Ayuda-Durán P, Piechaczyk L, Tadele DS, Baken L, Fredriksen J, Stoksflod M, Lenartova A, Fløisand Y, Skånland SS, Enserink JM (2023)
Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling
Cell Rep Methods, 3 (12), 100654
DOI 10.1016/j.crmeth.2023.100654, PubMed 38065095

Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS (2023)
Standardized assays to monitor drug sensitivity in hematologic cancers
Cell Death Discov, 9 (1), 435
DOI 10.1038/s41420-023-01722-5, PubMed 38040674

Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, Tveita AA, Taskén K, Munthe LA, Tjønnfjord GE, Skånland SS (2023)
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Cell Death Discov, 9 (1), 125
DOI 10.1038/s41420-023-01426-w, PubMed 37055391

Skånland SS, Brown JR (2023)
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Haematologica, 108 (1), 9-21
DOI 10.3324/haematol.2022.281266, PubMed 35899388

Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skånland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A (2023)
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
Blood, 141 (13), 1584-1596
DOI 10.1182/blood.2022016934, PubMed 36375120

Publications 2022

Aronson JH, Skånland SS, Roeker LE, Thompson MC, Mato AR (2022)
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)
Am J Hematol, 97 Suppl 2, S19-S25
DOI 10.1002/ajh.26682, PubMed 36125036

Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T (2022)
Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells
Methods Mol Biol, 2449, 327-348
DOI 10.1007/978-1-0716-2095-3_14, PubMed 35507270

Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG (2022)
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057

Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Front Oncol, 12, 1040730
DOI 10.3389/fonc.2022.1040730, PubMed 36523963

Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold F, Munthe LA, Taskén K (2022)
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
Mol Oncol, 16 (6), 1241-1258
DOI 10.1002/1878-0261.13191, PubMed 35148457

Imbery JF, Heinzelbecker J, Jebsen JK, McGowan M, Myklebust C, Bottini N, Stanford SM, Skånland SS, Tveita A, Tjønnfjord GE, Munthe LA, Szodoray P, Nakken B (2022)
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation
Br J Haematol, 198 (3), 556-573
DOI 10.1111/bjh.18285, PubMed 35655388

Skånland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tjønnfjord GE (2022)
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
Haematologica, 107 (8), 1994-1998
DOI 10.3324/haematol.2021.280393, PubMed 35236056

Skånland SS, Tjønnfjord GE (2022)
Determining drug dose in the era of targeted therapies: playing it (un)safe?
Blood Cancer J, 12 (8), 123
DOI 10.1038/s41408-022-00720-7, PubMed 35999205

Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland SS (2022)
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Clin Cancer Res, 28 (20), 4444-4455
DOI 10.1158/1078-0432.CCR-22-1221, PubMed 35998013

Publications 2021

Jiang X, Bergquist A, Löscher BS, Venkatesh G, Mold JE, Holm K, Laerdahl JK, Skånland SS, Maleki KT, Cornillet M, Taskén K, Franke A, Karlsen TH, Björkström NK, Melum E (2021)
A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
Sci Transl Med, 13 (582)
DOI 10.1126/scitranslmed.abb0036, PubMed 33627483

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096

Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D et al. (2021)
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Blood, 138 (18), 1768-1773
DOI 10.1182/blood.2021011841, PubMed 34297826

Skånland SS, Mato AR (2021)
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Blood Adv, 5 (1), 334-343
DOI 10.1182/bloodadvances.2020003423, PubMed 33570649

Publications 2020

Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR et al. (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood, 136 (10), 1134-1143
DOI 10.1182/blood.2020006965, PubMed 32688395

Skånland SS, Karlsen L, Taskén K (2020)
B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia
Scand J Immunol, 92 (5), e12931
DOI 10.1111/sji.12931, PubMed 32640099

Publications 2019

Skånland SS, Cieślar-Pobuda A (2019)
Off-label uses of drugs for depression
Eur J Pharmacol, 865, 172732
DOI 10.1016/j.ejphar.2019.172732, PubMed 31622593

Skånland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, Tjønnfjord GE, Taskén K (2019)
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
Leukemia, 34 (2), 478-487
DOI 10.1038/s41375-019-0569-7, PubMed 31471562

Skånland SS, Taskén K (2019)
Carboxyl-Terminal Src Kinase Binds CD28 upon Activation and Mutes Downstream Signaling
J Immunol, 203 (4), 1055-1063
DOI 10.4049/jimmunol.1801660, PubMed 31292214

Publications 2018

Hermansen JU, Tjønnfjord GE, Munthe LA, Taskén K, Skånland SS (2018)
Cryopreservation of primary B cells minimally influences their signaling responses
Sci Rep, 8 (1), 17651
DOI 10.1038/s41598-018-36121-9, PubMed 30518828

Myhrvold IK, Cremaschi A, Hermansen JU, Tjønnfjord GE, Munthe LA, Taskén K, Skånland SS (2018)
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia
Oncotarget, 9 (10), 9273-9284
DOI 10.18632/oncotarget.23949, PubMed 29507689

Skånland SS (2018)
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
J Vis Exp (140)
DOI 10.3791/58386, PubMed 30346411

Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304

Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2015

Parente-Ribes A, Skånland SS, Bürgler S, Os A, Wang D, Bogen B, Tjønnfjord GE, Taskén K, Munthe LA (2015)
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells
Haematologica, 101 (2), e59-62
DOI 10.3324/haematol.2015.135590, PubMed 26589914

Publications 2014

Skånland SS, Moltu K, Berge T, Aandahl EM, Taskén K (2014)
T-cell co-stimulation through the CD2 and CD28 co-receptors induces distinct signalling responses
Biochem J, 460 (3), 399-410
DOI 10.1042/BJ20140040, PubMed 24665965

Publications 2013

Gregers TF, Skånland SS, Wälchli S, Bakke O, Sandvig K (2013)
BiP negatively affects ricin transport
Toxins (Basel), 5 (5), 969-82
DOI 10.3390/toxins5050969, PubMed 23666197

Publications 2012

Kalland ME, Solheim SA, Skånland SS, Taskén K, Berge T (2012)
Modulation of proximal signaling in normal and transformed B cells by transmembrane adapter Cbp/PAG
Exp Cell Res, 318 (14), 1611-9
DOI 10.1016/j.yexcr.2012.05.014, PubMed 22659621

Pollheimer J, Bodin J, Sundnes O, Edelmann RJ, Skånland SS, Sponheim J, Brox MJ, Sundlisaeter E, Loos T, Vatn M, Kasprzycka M, Wang J, Küchler AM, Taskén K, Haraldsen G, Hol J (2012)
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells
Arterioscler Thromb Vasc Biol, 33 (2), e47-55
DOI 10.1161/ATVBAHA.112.253427, PubMed 23162017

Tcatchoff L, Andersson S, Utskarpen A, Klokk TI, Skånland SS, Pust S, Gerke V, Sandvig K (2012)
Annexin A1 and A2: roles in retrograde trafficking of Shiga toxin
PLoS One, 7 (7), e40429
DOI 10.1371/journal.pone.0040429, PubMed 22792315

Publications 2011

Ikeda F, Deribe YL, Skånland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I (2011)
SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis
Nature, 471 (7340), 637-41
DOI 10.1038/nature09814, PubMed 21455181

Publications 2010

Bethani I, Skånland SS, Dikic I, Acker-Palmer A (2010)
Spatial organization of transmembrane receptor signalling
EMBO J, 29 (16), 2677-88
DOI 10.1038/emboj.2010.175, PubMed 20717138

Publications 2009

Skånland SS, Wälchli S, Brech A, Sandvig K (2009)
SNX4 in complex with clathrin and dynein: implications for endosome movement
PLoS One, 4 (6), e5935
DOI 10.1371/journal.pone.0005935, PubMed 19529763

Skånland SS, Wälchli S, Sandvig K (2009)
β-arrestins attenuate p38-mediated endosome to Golgi transport
Cell Microbiol, 11 (5), 796-807
DOI 10.1111/j.1462-5822.2009.01292.x, PubMed 19159388

Wälchli S, Aasheim HC, Skånland SS, Spilsberg B, Torgersen ML, Rosendal KR, Sandvig K (2009)
Characterization of clathrin and Syk interaction upon Shiga toxin binding
Cell Signal, 21 (7), 1161-8
DOI 10.1016/j.cellsig.2009.03.005, PubMed 19289168

Publications 2008

Skånland SS (2008)
Mechanisms in intracellular transport of toxins
In Series of dissertations submitted to the Faculty of Mathematics and Natural Sciences, University of Oslo, The Faculty, Oslo, nr. 818, 1 b. (flere pag.)
BIBSYS 090016602

Publications 2007

Ménétret JF, Schaletzky J, Clemons WM, Osborne AR, Skånland SS, Denison C, Gygi SP, Kirkpatrick DS, Park E, Ludtke SJ, Rapoport TA, Akey CW (2007)
Ribosome binding of a single copy of the SecY complex: implications for protein translocation
Mol Cell, 28 (6), 1083-92
DOI 10.1016/j.molcel.2007.10.034, PubMed 18158904

Skånland SS, Wälchli S, Utskarpen A, Wandinger-Ness A, Sandvig K (2007)
Phosphoinositide-regulated retrograde transport of ricin: crosstalk between hVps34 and sorting nexins
Traffic, 8 (3), 297-309
DOI 10.1111/j.1600-0854.2006.00527.x, PubMed 17319803

Torgersen ML, Wälchli S, Grimmer S, Skånland SS, Sandvig K (2007)
Protein kinase Cdelta is activated by Shiga toxin and regulates its transport
J Biol Chem, 282 (22), 16317-28
DOI 10.1074/jbc.M610886200, PubMed 17403690

Utskarpen A, Slagsvold HH, Dyve AB, Skånland SS, Sandvig K (2007)
SNX1 and SNX2 mediate retrograde transport of Shiga toxin
Biochem Biophys Res Commun, 358 (2), 566-70
DOI 10.1016/j.bbrc.2007.04.159, PubMed 17498660

Wälchli S, Skånland SS, Gregers TF, Lauvrak SU, Torgersen ML, Ying M, Kuroda S, Maturana A, Sandvig K (2007)
The Mitogen-activated protein kinase p38 links Shiga Toxin-dependent signaling and trafficking
Mol Biol Cell, 19 (1), 95-104
DOI 10.1091/mbc.e07-06-0565, PubMed 17959827

Publications 2005

Skånland SS (2005)
The PI 3-kinase hVps34 modulates endosomes to Golgi transport of ricin
S.S. Skånland, Oslo, 47, 23 s.
BIBSYS 050613553